Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

ATRA

Atara Biotherapeutics Inc

May 02 • 04:00PM ET

0.6503

Dollar change -0.0342
Percentage change -5.00	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN SCHA VTWO VHT IWC FESM IWO

Index	RUT	P/E	-	EPS (ttm)	-2.61	Insider Own	7.74%	Shs Outstand	119.36M	Perf Week	-7.07%
Market Cap	77.62M	Forward P/E	-	EPS next Y	-0.40	Insider Trans	8.23%	Shs Float	110.12M	Perf Month	-9.68%
Income	-276.13M	PEG	-	EPS next Q	-0.26	Inst Own	60.30%	Short Float	10.39%	Perf Quarter	-21.65%
Sales	8.57M	P/S	9.06	EPS this Y	79.08%	Inst Trans	-0.33%	Short Ratio	5.94	Perf Half Y	-49.59%
Book/sh	-0.93	P/B	-	EPS next Y	26.01%	ROA	-101.91%	Short Interest	11.45M	Perf Year	-74.79%
Cash/sh	0.43	P/C	1.50	EPS next 5Y	-	ROE	-2014.86%	52W Range	0.20 - 3.02	Perf YTD	26.81%
Dividend Est.	2.00 (307.55%)	P/FCF	-	EPS past 5Y	13.12%	ROI	-	52W High	-78.43%	Beta	0.58
Dividend TTM	-	Quick Ratio	0.65	Sales past 5Y	25.21%	Gross Margin	-99.79%	52W Low	227.44%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	0.72	EPS Y/Y TTM	-16.73%	Oper. Margin	-3140.98%	RSI (14)	41.14	Volatility	9.86% 8.84%
Employees	225	Debt/Eq	-	Sales Y/Y TTM	-86.51%	Profit Margin	-3220.88%	Recom	2.60	Target Price	4.20
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	22.66%	Payout	-	Rel Volume	0.86	Prev Close	0.68
Sales Surprise	65.96%	EPS Surprise	-25.84%	Sales Q/Q	1823.98%	Earnings	Mar 28 BMO	Avg Volume	1.93M	Price	0.65
SMA20	-8.63%	SMA50	-8.60%	SMA200	-38.61%	Trades		Volume	2,214,549	Change	-5.00%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-09-23	Downgrade	Mizuho	Buy → Neutral	$31 → $1
Nov-09-23	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-09-23	Downgrade	Evercore ISI	Outperform → In-line
Jul-20-22	Downgrade	Citigroup	Neutral → Sell	$8 → $3
Jul-13-22	Downgrade	Stifel	Buy → Hold	$16 → $5
Jul-13-22	Downgrade	JP Morgan	Overweight → Neutral	$10
May-10-22	Downgrade	Citigroup	Buy → Neutral	$15 → $8
May-13-21	Upgrade	JP Morgan	Neutral → Overweight	$23 → $29
Dec-09-20	Downgrade	Citigroup	Buy → Neutral	$20 → $27
Dec-08-20	Reiterated	H.C. Wainwright	Buy	$28 → $31
Nov-10-20	Reiterated	H.C. Wainwright	Buy	$26 → $28
Jun-30-20	Initiated	Evercore ISI	Outperform
Jun-15-20	Initiated	H.C. Wainwright	Buy	$25
Apr-23-20	Upgrade	Citigroup	Neutral → Buy	$14
Nov-08-19	Downgrade	JP Morgan	Overweight → Neutral	$43 → $22
Sep-27-19	Downgrade	Goldman	Neutral → Sell	$14 → $9
Sep-16-19	Downgrade	Jefferies	Buy → Hold	$32 → $15
Jun-04-19	Upgrade	Citigroup	Sell → Neutral	$23 → $24
May-30-19	Initiated	ROTH Capital	Buy
May-23-19	Initiated	Stifel	Buy

Show Previous Ratings

Apr-05-24 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-28-24 01:53PM	ATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
09:40AM	Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:40AM	Atara Biotherapeutics: Q4 Earnings Snapshot (Associated Press Finance)
08:30AM	Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress (Business Wire)
09:05AM	Loading…
Feb-29-24 09:05AM	Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy (Business Wire)
Feb-28-24 04:30PM	Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference (Business Wire)
Feb-14-24 09:00AM	Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis (Business Wire)
Jan-31-24 06:30PM	Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel Data in The Lancet Oncology (Business Wire)
Jan-11-24 01:26AM	Seth Klarman's Firm Exits Atara Biotherapeutics Inc Holding (GuruFocus.com) +5.31%
01:26AM	Seth Klarman's Exit from Atara Biotherapeutics Inc (GuruFocus.com)
Jan-08-24 09:00AM	Atara Biotherapeutics Announces $15 Million Registered Direct Offering (Business Wire) +25.28%
08:00AM	Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-04-24 04:01PM	Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-20-23 04:01PM	Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel Partnership with Pierre Fabre Laboratories (Business Wire)
12:00PM	Loading…
Dec-11-23 12:00PM	Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting (Business Wire)
Dec-01-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-29-23 06:05PM	Atara Biotherapeutics To Present Positive New Tab-cel Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023 (Business Wire) +13.36%
Nov-24-23 12:29PM	Atara Biotherapeutics (ATRA) Slumps 57% in a Month: Here's Why (Zacks) +13.93%
Nov-22-23 04:01PM	Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference (Business Wire) +13.22%
09:14AM	Billionaire Seth Klarmans Biotech Stock Picks (Insider Monkey)
Nov-10-23 04:01PM	Atara Biotherapeutics To Participate at the Stifel Healthcare Conference (Business Wire)
Nov-09-23 08:23AM	Why Is Atara Biotherapeutics (ATRA) Stock Down 50% Today? (InvestorPlace) -80.17%
06:40AM	Ataras cell therapy approach to MS falls short in study (BioPharma Dive)
Nov-08-23 05:35PM	Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis (Business Wire) -9.02%
Nov-05-23 12:50PM	Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 05:42AM	Atara Biotherapeutics Inc (ATRA) Announces Q3 2023 Financial Results and Expanded Global Partnership (GuruFocus.com) -5.56%
02:25AM	Q3 2023 Atara Biotherapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-01-23 08:35AM	Atara Biotherapeutics: Q3 Earnings Snapshot (Associated Press Finance)
08:30AM	Atara Biotherapeutics Announces Expanded Global Tab-cel Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results (Business Wire)
04:01PM	Loading…
Oct-06-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-21-23 09:19AM	Atara (ATRA) Up 11% on Regulatory Update From Blood Cancer Study (Zacks)
Sep-19-23 04:01PM	Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability (Business Wire)
Sep-01-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.16%
Aug-31-23 04:01PM	Atara Biotherapeutics to Participate in Cell Therapies in Autoimmune Panel Discussion at the Citi 18th Annual BioPharma Conference (Business Wire)
Aug-13-23 10:44AM	10 Most Promising Penny Stocks According to Analysts (Insider Monkey)
Aug-08-23 05:30PM	Atara Biotherapeutics (ATRA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:18PM	Atara Biotherapeutics: Q2 Earnings Snapshot (AP Finance)
04:01PM	Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress (Business Wire)
Aug-04-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-01-23 04:01PM	Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023 (Business Wire)
Jul-31-23 04:01PM	Atara Biotherapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference (Business Wire) +7.28%
Jul-29-23 11:07AM	10 Stocks That Will Go Up 1000 Percent (Insider Monkey)
Jul-17-23 07:29AM	3 Doomed Biotech Stocks Destined for Disaster (InvestorPlace) +6.56%
Jul-07-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +11.45%
Jun-16-23 06:05AM	Time To Worry? Analysts Just Downgraded Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Outlook (Simply Wall St.) -6.07%
Jun-07-23 04:01PM	Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference (Business Wire)
Jun-05-23 09:00AM	Atara Biotherapeutics Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023 (Business Wire)
Jun-02-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-18-23 07:09AM	Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Analysts Are More Bearish Than They Used To Be (Simply Wall St.)
May-08-23 05:15PM	Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:12PM	Atara Biotherapeutics: Q1 Earnings Snapshot (AP Finance)
04:01PM	Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress (Business Wire)
May-07-23 08:59AM	The Market Doesn't Like What It Sees From Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Revenues Yet (Simply Wall St.)
May-05-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.82%
May-01-23 04:01PM	Atara Biotherapeutics to Announce First Quarter 2023 Financial Results on Monday, May 8, 2023 (Business Wire)
Apr-16-23 12:08PM	3 Stocks to Buy That Could Be the Next Biotech Breakthrough (InvestorPlace)
Mar-31-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-24-23 09:35AM	Atara Biotherapeutics (ATRA) Loses -33.02% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Mar-03-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:40AM	Are Medical Stocks Lagging Apexigen, Inc. (APGN) This Year? (Zacks)
Mar-01-23 04:01PM	Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 43rd Annual Health Care Conference (Business Wire)
Feb-21-23 04:01PM	Atara Biotherapeutics to Participate in the H.C. Wainwright Cell Therapy Virtual Conference (Business Wire) -9.96%
Feb-15-23 06:58AM	The past five years for Atara Biotherapeutics (NASDAQ:ATRA) investors has not been profitable (Simply Wall St.)
Feb-08-23 05:15PM	Atara Biotherapeutics (ATRA) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -7.69%
04:01PM	Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress (Business Wire)
06:00AM	Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO (tabelecleucel) (Business Wire)
Feb-06-23 08:00AM	Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023 (Business Wire)
Feb-03-23 04:01PM	Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.31%
Jan-13-23 04:01PM	Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-04-23 04:01PM	Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-24-22 10:07AM	3 Under-the-Radar Biotech Stocks to Buy in 2022 (Motley Fool)
Dec-20-22 04:33PM	Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty (Business Wire)
Dec-19-22 08:00AM	Atara Biotherapeutics Announces Changes to Its Board of Directors (Business Wire)
07:00AM	Atara Biotherapeutics Ebvallo (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD (Business Wire)
Dec-15-22 04:01PM	Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -10.82%
Dec-12-22 10:00AM	Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual Meeting (Business Wire)
Dec-02-22 04:01PM	Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +8.18%
Nov-23-22 08:00AM	Atara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx Conference (Business Wire)
Nov-22-22 05:03AM	Newsflash: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Analysts Have Been Trimming Their Revenue Forecasts (Simply Wall St.)
Nov-10-22 05:52AM	Atara Biotherapeutics Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS In Line (Simply Wall St.) +23.97%
Nov-09-22 04:01PM	Atara Biotherapeutics to Participate at the Stifel Healthcare Conference (Business Wire) -20.82%
Nov-08-22 05:15PM	Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress (Business Wire)
Nov-04-22 04:01PM	Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-01-22 04:05PM	Atara Biotherapeutics to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022 (Business Wire)
Oct-26-22 02:01AM	Atara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022 (Business Wire)
Oct-14-22 07:08AM	CHMP Recommends Approval of Atara Biotherapeutics Ebvallo (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (Business Wire) -6.52%
Oct-13-22 12:51PM	BioMarin (BMRN) Hemophilia Gene Therapy BLA Gets FDA Acceptance (Zacks)
Oct-10-22 04:01PM	Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-07-22 10:01AM	Allogene (ALLO) Begins Phase II Study on Allogeneic CAR T Therapy (Zacks) -8.61%
Oct-06-22 01:36PM	Acadia (ACAD) Rises More Than 14% in 3 Months: Here's Why (Zacks)
Sep-30-22 08:59AM	Horizon (HZNP) Completes Enrollment in Phase IV TED Study (Zacks)
Sep-29-22 11:09AM	Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis (Zacks) -5.47%
07:30AM	Atara Biotherapeutics to Receive Additional Near-Term Milestone Under Updated Tab-cel Commercialization Pact (Benzinga)
Sep-28-22 04:01PM	Atara Biotherapeutics to Receive Additional Near-Term Milestone Payment Under Updated Tabelecleucel (Tab-cel®) Commercialization Agreement with Pierre Fabre (Business Wire) +15.32%
01:47PM	Merck's (MRK) Keytruda Gets Four New Approvals in Japan (Zacks)
Sep-27-22 10:13AM	Emergent (EBS) Acquires Worldwide Rights to Smallpox Antiviral (Zacks)
Sep-21-22 06:32PM	Alnylam's (ALNY) Rare Disease Drug Amvuttra Gets EC Nod (Zacks) -5.53%
Sep-13-22 03:45PM	Horizon's (HZNP) Phase II Sjogren's Syndrome Study Meets Goal (Zacks) -6.92%

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Touchon Pascal	President and CEO	Mar 04 '24	Sale	0.72	24,844	17,888	1,910,652	Mar 06 06:19 PM
Nguyen AnhCo	EVP, Chief Sci. & Tech Officer	Mar 04 '24	Sale	0.72	10,746	7,737	941,397	Mar 06 06:18 PM
Murugan Amar	EVP, Chief Legal Officer	Mar 04 '24	Sale	0.72	10,044	7,232	727,521	Mar 06 06:18 PM
Henrich Jill	EVP, Global Head RA & Quality	Mar 04 '24	Sale	0.72	3,879	2,793	555,001	Mar 06 06:16 PM
Touchon Pascal	President and CEO	Nov 16 '23	Sale	0.39	20,409	7,939	655,496	Nov 20 05:31 PM
Joshi Manher	EVP, Chief Medical Officer	Nov 16 '23	Sale	0.39	12,287	4,780	171,284	Nov 20 05:30 PM
Hyllengren Eric J	SVP, CFO	Nov 16 '23	Sale	0.39	11,958	4,652	205,998	Nov 20 05:29 PM
Nguyen AnhCo	EVP, Chief Sci. & Tech Officer	Nov 16 '23	Sale	0.39	8,856	3,445	277,143	Nov 20 05:31 PM
Murugan Amar	EVP, Chief Legal Officer	Nov 16 '23	Sale	0.39	8,307	3,231	257,084	Nov 20 05:30 PM
Henrich Jill	EVP, Global Head RA & Quality	Nov 16 '23	Sale	0.39	3,267	1,271	104,424	Nov 20 05:29 PM
Gallagher Carol Giltner	Director	Nov 14 '23	Buy	0.31	90,980	28,186	459,418	Nov 15 05:07 PM
Gallagher Carol Giltner	Director	Nov 13 '23	Buy	0.22	179,020	40,029	368,438	Nov 15 05:07 PM
DOBMEIER ERIC	Director	Nov 10 '23	Buy	0.23	446,825	101,340	563,325	Nov 14 06:27 PM
HEIDEN WILLIAM K	Director	Nov 10 '23	Buy	0.25	100,000	25,330	209,000	Nov 14 06:29 PM
Touchon Pascal	President and CEO	Aug 16 '23	Sale	1.65	30,766	50,835	675,905	Aug 18 06:25 PM
Nguyen AnhCo	EVP, Chief Sci. & Tech Officer	Aug 16 '23	Sale	1.65	15,126	24,997	285,999	Aug 18 06:25 PM
Murugan Amar	EVP, Chief Legal Officer	Aug 16 '23	Sale	1.65	8,672	14,330	265,391	Aug 18 06:25 PM
Hyllengren Eric J	SVP, CFO	Aug 16 '23	Sale	1.65	8,186	13,527	217,956	Aug 18 06:25 PM
Joshi Manher	EVP, Chief Medical Officer	Aug 16 '23	Sale	1.65	6,975	11,526	183,571	Aug 18 06:25 PM
Henrich Jill	EVP, Global Head RA & Quality	Aug 16 '23	Sale	1.65	3,346	5,531	107,691	Aug 18 06:25 PM
Touchon Pascal	President and CEO	Jun 27 '23	Sale	1.66	14,291	23,723	706,671	Jun 29 04:15 PM
Touchon Pascal	President and CEO	May 16 '23	Sale	2.04	29,766	60,633	720,962	May 18 08:17 PM
Banard Charlene A.	EVP, Chief Technical Officer	May 16 '23	Sale	2.04	19,040	38,784	276,010	May 18 08:17 PM
Murugan Amar	EVP, Chief Legal Officer	May 16 '23	Sale	2.04	8,389	17,089	270,945	May 18 08:17 PM
Hyllengren Eric J	SVP, CFO	May 16 '23	Sale	2.04	7,918	16,131	226,142	May 18 08:17 PM

Open in Screener

CRNX

Crinetics Pharmaceuticals Inc

May 02 • 04:00PM ET

46.78

Dollar change +1.73
Percentage change 3.84	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

CRNX Crinetics Pharmaceuticals Inc daily Stock Chart

Held by: VTI IWM VXF IBB IWN SCHA VTWO VHT LABU IWC

Index	RUT	P/E	-	EPS (ttm)	-3.70	Insider Own	7.45%	Shs Outstand	77.93M	Perf Week	10.62%
Market Cap	3.65B	Forward P/E	-	EPS next Y	-3.54	Insider Trans	-7.14%	Shs Float	72.12M	Perf Month	-1.76%
Income	-214.53M	PEG	-	EPS next Q	-0.81	Inst Own	89.80%	Short Float	7.24%	Perf Quarter	25.72%
Sales	0.00M	P/S	-	EPS this Y	13.21%	Inst Trans	1.42%	Short Ratio	6.44	Perf Half Y	59.71%
Book/sh	7.91	P/B	5.92	EPS next Y	-10.42%	ROA	-43.45%	Short Interest	5.22M	Perf Year	124.26%
Cash/sh	7.17	P/C	6.53	EPS next 5Y	-	ROE	-50.16%	52W Range	15.76 - 49.58	Perf YTD	31.48%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-10.59%	ROI	-36.57%	52W High	-5.65%	Beta	0.65
Dividend TTM	-	Quick Ratio	13.07	Sales past 5Y	64.83%	Gross Margin	-105.50%	52W Low	196.83%	ATR (14)	2.23
Dividend Ex-Date	-	Current Ratio	13.07	EPS Y/Y TTM	-17.50%	Oper. Margin	0.00%	RSI (14)	60.07	Volatility	4.97% 4.93%
Employees	290	Debt/Eq	0.10	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.21	Target Price	57.14
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	-7.10%	Payout	-	Rel Volume	0.75	Prev Close	45.05
Sales Surprise	-100.00%	EPS Surprise	-4.35%	Sales Q/Q	-100.00%	Earnings	May 09 AMC	Avg Volume	811.42K	Price	46.78
SMA20	4.95%	SMA50	8.25%	SMA200	44.94%	Trades		Volume	609,233	Change	3.84%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-06-24	Initiated	Citigroup	Buy	$68
Jan-16-24	Initiated	Morgan Stanley	Overweight	$50
Dec-21-23	Initiated	Jefferies	Hold	$35
Nov-20-23	Resumed	JP Morgan	Overweight	$35
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$52 → $50
Aug-31-23	Initiated	Oppenheimer	Outperform	$40
Apr-24-23	Initiated	Piper Sandler	Overweight	$56
Mar-30-23	Initiated	Robert W. Baird	Outperform	$48
Nov-30-21	Initiated	JMP Securities	Mkt Outperform	$43
Nov-23-21	Initiated	Evercore ISI	Outperform	$68
Jun-18-21	Upgrade	JP Morgan	Neutral → Overweight	$28
Dec-23-19	Initiated	ROTH Capital	Buy	$37
Feb-14-19	Initiated	H.C. Wainwright	Buy	$35
Aug-13-18	Initiated	Piper Jaffray	Overweight	$40
Aug-13-18	Initiated	Leerink Partners	Outperform	$43
Aug-13-18	Initiated	JP Morgan	Neutral	$29

Show Previous Ratings

May-02-24 04:05PM	Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024 (GlobeNewswire)
Apr-11-24 04:05PM	Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-28-24 08:10AM	Insiders Are Dumping These 5 Healthcare Stocks (Insider Monkey) +5.36%
Mar-26-24 07:01PM	Insider Sell: COO Jeff Knight Sells 32,359 Shares of Crinetics Pharmaceuticals Inc (CRNX) (GuruFocus.com)
Mar-22-24 07:02PM	Insider Sell: Chief Medical and Development Officer Dana Pizzuti Sells 15,089 Shares of ... (GuruFocus.com)
07:02PM	Loading…
07:02PM	Director Matthew Fust Sells 60,000 Shares of Crinetics Pharmaceuticals Inc (CRNX) (GuruFocus.com)
Mar-21-24 02:32AM	Crinetics Pharmaceuticals Inc CFO Marc Wilson Sells 6,942 Shares (GuruFocus.com)
Mar-20-24 11:46AM	Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals (Zacks)
05:14AM	Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar? (Zacks)
Mar-19-24 04:48PM	Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why (Benzinga) +19.11%
04:03PM	Crinetics Stock Jets 19% Higher, Reversing A Three-Week Decline On Its Phase 3 Win (Investor's Business Daily)
08:08AM	Biotech Stock Crinetics Jets Higher On Second Phase 3 Trial Win (Investor's Business Daily)
06:16AM	UPDATE 2-Crinetics' hormonal disorder drug succeeds in late-stage study (Reuters)
06:08AM	Crinetics Pharma's hormonal disorder drug meets main goal in late-stage study (Reuters)
06:00AM	Crinetics' Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients (GlobeNewswire)
04:05PM	Loading…
Mar-12-24 04:05PM	Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome (GlobeNewswire)
Mar-11-24 04:05PM	Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-01-24 08:57AM	Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2023 Earnings Call Transcript (Insider Monkey) +12.43%
Feb-28-24 04:36PM	Crinetics Pharmaceuticals Inc (CRNX) Reports Increased R&D Investment Amidst Net Loss ... (GuruFocus.com) +5.66%
04:05PM	Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
08:00AM	Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement (GlobeNewswire)
Feb-15-24 03:14AM	Steven Cohen Adjusts Position in Crinetics Pharmaceuticals Inc (GuruFocus.com)
Feb-14-24 04:05PM	Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 (GlobeNewswire)
Feb-12-24 04:05PM	Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-26-24 11:01PM	Crinetics Pharmaceuticals Inc's Chief Scientific Officer Sells Company Shares (GuruFocus.com)
Jan-13-24 05:03AM	Crinetics Pharmaceuticals Inc Insider Sells Shares (GuruFocus.com)
Jan-10-24 04:33PM	Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-05-24 03:03AM	Insider Sell: Chief Med and Dev Officer Dana Pizzuti Sells 14,375 Shares of Crinetics ... (GuruFocus.com)
Jan-03-24 08:00AM	Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-29-23 07:02AM	Crinetics Pharmaceuticals Inc's Chief Scientific Officer Sells Shares (GuruFocus.com)
05:01AM	Loading…
Dec-23-23 05:01AM	Insider Sell: Chief Med and Dev Officer Dana Pizzuti Sells 9,583 Shares of Crinetics ... (GuruFocus.com)
Dec-18-23 04:05PM	Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome (GlobeNewswire)
Dec-11-23 04:05PM	Crinetics Pharmaceuticals Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-03-23 05:25AM	12 Stocks Billionaire Steve Cohen Just Bought and Sold (Insider Monkey)
Nov-20-23 04:05PM	Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-17-23 08:39AM	Billionaire Steve Cohen Goes Big on These 2 Strong Buy Stocks Heres Why You Should Follow (TipRanks) +5.82%
Nov-10-23 05:00PM	Crinetics Pharmaceuticals Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-09-23 05:45AM	Crinetics Pharmaceuticals Inc (CRNX) Reports Q3 2023 Results: Phase 3 Success and Financial Growth (GuruFocus.com) -6.19%
Nov-08-23 09:55AM	Wall Street Analysts See a 56.94% Upside in Crinetics Pharmaceuticals, Inc. (CRNX): Can the Stock Really Move This High? (Zacks)
08:50AM	Here's What Could Help Crinetics Pharmaceuticals, Inc. (CRNX) Maintain Its Recent Price Strength (Zacks)
Nov-07-23 04:05PM	Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-04-23 05:03AM	Insider Sell: CFO Marc Wilson Sells 10,000 Shares of Crinetics Pharmaceuticals Inc (CRNX) (GuruFocus.com)
Oct-23-23 09:55AM	Wall Street Analysts Think Crinetics Pharmaceuticals, Inc. (CRNX) Could Surge 55.53%: Read This Before Placing a Bet (Zacks)
08:50AM	What Makes Crinetics Pharmaceuticals, Inc. (CRNX) a Good Fit for 'Trend Investing' (Zacks)
Oct-20-23 01:02AM	Insider Sell: Chief Medical Officer Alan Krasner Sells 7,000 Shares of Crinetics Pharmaceuticals Inc (GuruFocus.com) +5.92%
Oct-11-23 09:00AM	Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment (PR Newswire)
Oct-10-23 05:00PM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-03-23 07:00AM	7 Speculative Stocks Set to Explode Higher (InvestorPlace)
Sep-28-23 11:18AM	Crinetics (CRNX) Stock Surges 70% in a Month: Here's Why (Zacks)
Sep-20-23 08:00AM	Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023 (GlobeNewswire)
Sep-15-23 08:37AM	Why Crinetics Pharmaceuticals Stock Soared This Week (Motley Fool)
Sep-12-23 10:26PM	Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire) +17.29%
Sep-11-23 04:04PM	Crinetics Pharmaceuticals Just Scored A Much-Needed Win And Soared 63% (Investor's Business Daily) +63.31%
04:01PM	Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock (GlobeNewswire)
12:57PM	Why Shares of Crinetics Pharmaceuticals Are Jumping Monday (Motley Fool)
06:00AM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
05:43AM	Crinetics shares surge after "positive" hormonal disorder drug trial results (Investing.com)
Sep-10-23 10:00AM	Crinetics Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly (GlobeNewswire)
Sep-05-23 08:55PM	Oppenheimer Says These 2 Stocks Could Double Your Money Heres Why They Could Jump (TipRanks)
Aug-13-23 09:02AM	Will Crinetics Pharmaceuticals (NASDAQ:CRNX) Spend Its Cash Wisely? (Simply Wall St.)
Aug-10-23 05:34PM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-08-23 07:00AM	Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-31-23 08:01AM	Crinetics Hosting Key Opinion Leader Webinar to Discuss the Current Treatment Landscape and Unmet Need in Acromegaly (GlobeNewswire)
Jul-10-23 04:18PM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.73%
Jun-21-23 07:59AM	New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023 (GlobeNewswire)
Jun-12-23 07:30AM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-09-23 07:30AM	Crinetics to Highlight Broad Pipeline at ENDO 2023 (GlobeNewswire)
May-10-23 04:21PM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-06-23 08:07AM	Crinetics Pharmaceuticals First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
May-04-23 07:35PM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
10:00AM	Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q1 Earnings Expected to Decline (Zacks)
Apr-16-23 09:34AM	The past year for Crinetics Pharmaceuticals (NASDAQ:CRNX) investors has not been profitable (Simply Wall St.)
Apr-10-23 04:31PM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-28-23 03:57PM	Top 10 Growth Stocks in Biotech (Insider Monkey)
Mar-10-23 04:37PM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.05%
Mar-06-23 07:05AM	We Think Crinetics Pharmaceuticals (NASDAQ:CRNX) Can Afford To Drive Business Growth (Simply Wall St.)
Feb-28-23 05:25PM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-10-23 05:21PM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:01AM	Crinetics Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-10-23 04:48PM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-09-23 08:01AM	Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.59%
Dec-12-22 04:01PM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-28-22 08:00AM	Crinetics Pharmaceuticals Provides Update on CRN04777 Program (GlobeNewswire) -5.86%
Nov-22-22 08:00AM	Crinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-14-22 09:15AM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:00AM	Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-10-22 04:30PM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.52%
Nov-06-22 07:26AM	Shareholders in Crinetics Pharmaceuticals (NASDAQ:CRNX) are in the red if they invested a year ago (Simply Wall St.)
Oct-13-22 08:00AM	Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly (GlobeNewswire)
Oct-10-22 04:57PM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-06-22 08:00AM	Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism (GlobeNewswire)
Oct-03-22 08:00AM	Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer (GlobeNewswire)
Sep-26-22 10:29AM	We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate (Simply Wall St.)
Sep-12-22 08:00AM	Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-08-22 08:00AM	Crinetics Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Sep-06-22 08:00AM	New Long-Term Safety and Efficacy Data Presented with Paltusotine in Participants Living with Acromegaly (GlobeNewswire)
Sep-02-22 08:00AM	New Long-Term Safety and Efficacy Data for Investigational Compound Paltusotine to be Presented at the Brazilian Congress of Endocrinology and Metabolism (GlobeNewswire)
Aug-12-22 09:15AM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pizzuti Dana	Chief Med and Dev Officer	Apr 15 '24	Option Exercise	16.89	14,375	242,794	42,161	Apr 17 04:36 PM
Struthers Richard Scott	President & CEO	Apr 15 '24	Option Exercise	1.91	20,000	38,200	257,835	Apr 17 04:30 PM
Pizzuti Dana	Chief Med and Dev Officer	Apr 15 '24	Sale	44.47	14,375	639,256	27,786	Apr 17 04:36 PM
Struthers Richard Scott	President & CEO	Apr 04 '24	Option Exercise	9.28	40,951	380,025	278,786	Apr 08 05:09 PM
Struthers Richard Scott	President & CEO	Apr 04 '24	Sale	49.17	40,951	2,013,561	237,835	Apr 08 05:09 PM
Okey Stephanie	Director	Mar 28 '24	Option Exercise	18.29	17,500	320,075	23,500	Apr 02 04:35 PM
Okey Stephanie	Director	Mar 28 '24	Sale	46.38	17,500	811,650	6,000	Apr 02 04:35 PM
Knight Jeff E.	Chief Operating Officer	Mar 22 '24	Option Exercise	23.98	30,000	719,400	84,939	Mar 26 04:30 PM
Knight Jeff E.	Chief Operating Officer	Mar 22 '24	Sale	44.31	32,359	1,433,675	52,580	Mar 26 04:30 PM
Fust Matthew K	Director	Mar 20 '24	Option Exercise	20.92	60,000	1,254,975	36,036	Mar 22 04:31 PM
Pizzuti Dana	Chief Med and Dev Officer	Mar 20 '24	Option Exercise	16.89	14,375	242,794	38,500	Mar 22 04:52 PM
Fust Matthew K	Director	Mar 20 '24	Sale	44.14	60,000	2,648,150	18,536	Mar 22 04:31 PM
Pizzuti Dana	Chief Med and Dev Officer	Mar 20 '24	Sale	44.06	15,089	664,763	27,786	Mar 22 04:52 PM
Wilson Marc	CFO	Mar 19 '24	Sale	42.91	6,942	297,881	110,630	Mar 20 06:32 PM
Betz Stephen F.	Chief Scientific Officer	Jan 25 '24	Sale	37.26	3,000	111,780	73,298	Jan 26 05:50 PM
Betz Stephen F.	Chief Scientific Officer	Jan 10 '24	Sale	37.65	3,000	112,950	76,298	Jan 12 04:12 PM
Pizzuti Dana	Chief Med and Dev Officer	Jan 03 '24	Option Exercise	16.89	14,375	242,794	20,286	Jan 04 04:45 PM
Pizzuti Dana	Chief Med and Dev Officer	Jan 03 '24	Sale	35.00	14,375	503,125	5,911	Jan 04 04:45 PM
Wilson Marc	CFO	Jan 02 '24	Option Exercise	9.28	10,000	92,800	106,055	Jan 04 04:43 PM
Wilson Marc	CFO	Jan 02 '24	Sale	35.47	10,000	354,700	96,055	Jan 04 04:43 PM
Betz Stephen F.	Chief Scientific Officer	Dec 26 '23	Sale	35.89	3,000	107,670	79,298	Dec 27 05:20 PM
Pizzuti Dana	Chief Med and Dev Officer	Dec 21 '23	Option Exercise	16.89	9,583	161,857	15,494	Dec 22 06:45 PM
Pizzuti Dana	Chief Med and Dev Officer	Dec 21 '23	Sale	34.57	9,583	331,284	5,911	Dec 22 06:45 PM
Betz Stephen F.	Chief Scientific Officer	Dec 11 '23	Sale	32.87	3,000	98,610	82,298	Dec 13 04:44 PM
Betz Stephen F.	Chief Scientific Officer	Nov 27 '23	Sale	31.84	3,000	95,520	85,298	Nov 29 04:31 PM
Struthers Richard Scott	President & CEO	Nov 09 '23	Option Exercise	1.91	50,000	95,500	185,522	Nov 13 04:33 PM
Struthers Richard Scott	President & CEO	Nov 03 '23	Option Exercise	9.28	199,082	1,847,481	334,604	Nov 06 06:02 PM
Struthers Richard Scott	President & CEO	Nov 03 '23	Sale	30.56	199,082	6,083,946	135,522	Nov 06 06:02 PM
Struthers Richard Scott	President & CEO	Nov 02 '23	Option Exercise	9.28	918	8,519	136,440	Nov 06 06:02 PM
Struthers Richard Scott	President & CEO	Nov 02 '23	Sale	29.95	918	27,494	135,522	Nov 06 06:02 PM
Wilson Marc	CFO	Nov 01 '23	Option Exercise	9.28	10,000	92,800	105,601	Nov 03 07:38 PM
Wilson Marc	CFO	Nov 01 '23	Sale	28.75	10,000	287,500	95,601	Nov 03 07:38 PM
Krasner Alan Seth	Chief Medical Officer	Oct 17 '23	Option Exercise	12.01	7,000	84,070	50,210	Oct 19 05:01 PM
Krasner Alan Seth	Chief Medical Officer	Oct 17 '23	Sale	30.00	7,000	210,000	43,210	Oct 19 05:01 PM
Struthers Richard Scott	President & CEO	Aug 14 '23	Option Exercise	1.91	10,000	19,100	135,522	Aug 16 04:30 PM
Struthers Richard Scott	President & CEO	Jul 13 '23	Sale	20.35	14,157	288,095	630,805	Jul 13 04:56 PM
Struthers Richard Scott	President & CEO	Jul 12 '23	Sale	20.17	11,459	231,128	644,962	Jul 13 04:56 PM
Struthers Richard Scott	President & CEO	Jul 11 '23	Sale	20.14	24,384	491,094	656,421	Jul 13 04:56 PM
Wilson Marc	CFO	Jun 20 '23	Option Exercise	9.28	20,000	185,600	115,158	Jun 21 05:32 PM
Wilson Marc	CFO	Jun 20 '23	Sale	19.97	30,922	617,403	95,158	Jun 21 05:32 PM
Struthers Richard Scott	President & CEO	Jun 16 '23	Sale	20.81	50,000	1,040,500	680,805	Jun 21 05:27 PM
Vivaldi Coelho Rogerio	Director	Jun 08 '23	Buy	22.06	5,000	110,300	5,000	Jun 09 08:00 AM

Open in Screener

RARE

Ultragenyx Pharmaceutical Inc.

May 02 • 04:00PM ET

43.20

Dollar change -0.10
Percentage change -0.23	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

RARE Ultragenyx Pharmaceutical Inc. daily Stock Chart

Held by: VTI VB VXF VBK IBB SCHA IWP VHT IWF IWR

Index	-	P/E	-	EPS (ttm)	-8.33	Insider Own	6.45%	Shs Outstand	82.31M	Perf Week	-1.48%
Market Cap	3.56B	Forward P/E	-	EPS next Y	-5.05	Insider Trans	-1.83%	Shs Float	77.02M	Perf Month	-8.24%
Income	-606.64M	PEG	-	EPS next Q	-1.68	Inst Own	104.15%	Short Float	5.69%	Perf Quarter	-2.04%
Sales	434.25M	P/S	8.19	EPS this Y	21.24%	Inst Trans	-3.16%	Short Ratio	6.11	Perf Half Y	22.03%
Book/sh	3.35	P/B	12.91	EPS next Y	22.35%	ROA	-39.80%	Short Interest	4.38M	Perf Year	1.62%
Cash/sh	7.03	P/C	6.14	EPS next 5Y	8.90%	ROE	-193.23%	52W Range	31.52 - 54.98	Perf YTD	-9.66%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-15.75%	ROI	-51.92%	52W High	-21.43%	Beta	0.62
Dividend TTM	-	Quick Ratio	2.49	Sales past 5Y	63.06%	Gross Margin	88.54%	52W Low	37.06%	ATR (14)	1.98
Dividend Ex-Date	-	Current Ratio	2.61	EPS Y/Y TTM	17.65%	Oper. Margin	-131.08%	RSI (14)	41.78	Volatility	3.56% 4.85%
Employees	1276	Debt/Eq	3.39	Sales Y/Y TTM	19.52%	Profit Margin	-139.70%	Recom	1.29	Target Price	89.24
Option/Short	Yes / Yes	LT Debt/Eq	3.24	EPS Q/Q	29.83%	Payout	-	Rel Volume	1.13	Prev Close	43.30
Sales Surprise	-6.20%	EPS Surprise	-16.19%	Sales Q/Q	23.27%	Earnings	May 02 AMC	Avg Volume	717.57K	Price	43.20
SMA20	-5.42%	SMA50	-9.11%	SMA200	2.58%	Trades		Volume	805,187	Change	-0.23%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-22-24	Initiated	RBC Capital Mkts	Outperform	$77
Dec-08-23	Initiated	Wells Fargo	Overweight	$72
Jun-14-23	Resumed	Credit Suisse	Outperform	$96
Jun-06-23	Upgrade	Evercore ISI	In-line → Outperform	$60 → $80
Apr-26-23	Initiated	Cantor Fitzgerald	Overweight	$114
Jan-18-23	Resumed	Canaccord Genuity	Buy	$90
Dec-30-22	Resumed	H.C. Wainwright	Buy	$82
Nov-03-22	Upgrade	Robert W. Baird	Neutral → Outperform	$50
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy	$50
Aug-01-22	Downgrade	Evercore ISI	Outperform → In-line	$95 → $60
Mar-16-22	Upgrade	Credit Suisse	Neutral → Outperform	$99 → $105
Feb-11-22	Upgrade	JP Morgan	Neutral → Overweight	$132
Sep-30-21	Initiated	H.C. Wainwright	Buy	$106
Aug-19-21	Initiated	UBS	Sell	$73
Jul-15-21	Initiated	Guggenheim	Neutral
Jun-29-21	Upgrade	BofA Securities	Neutral → Buy	$162
Jun-04-21	Resumed	Robert W. Baird	Neutral	$109
May-06-21	Upgrade	Evercore ISI	In-line → Outperform	$144
May-06-21	Upgrade	Citigroup	Neutral → Buy	$160 → $151
Apr-26-21	Resumed	Credit Suisse	Neutral	$99

Show Previous Ratings

May-02-24 08:58PM	RARE Stock Earnings: Ultragenyx Pharmaceutical Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:00PM	Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:49PM	Ultragenyx Pharmaceutical Inc (RARE) Q1 2024 Earnings: Misses EPS Estimates, Revenue Grows ... (GuruFocus.com)
05:10PM	Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:08PM	Ultragenyx: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Loading…
04:00PM	Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update (GlobeNewswire)
Apr-30-24 04:00PM	Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease (GlobeNewswire)
08:00AM	Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) (GlobeNewswire)
Apr-25-24 04:30PM	Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update (GlobeNewswire)
Apr-19-24 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-16-24 11:33AM	Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study (Zacks)
Apr-15-24 07:30AM	Ultragenyx says Angelman therapy is working, but safety questions remain (BioPharma Dive) -8.79%
07:00AM	Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102 (GlobeNewswire)
Apr-12-24 04:22PM	Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome (GlobeNewswire) -7.30%
08:00AM	Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting (GlobeNewswire)
04:00PM	Loading…
Mar-22-24 04:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-20-24 08:11AM	10 NASDAQ Stocks with Biggest Upside (Insider Monkey)
Mar-12-24 05:00PM	Insider Sell: CBO & EVP Thomas Kassberg Sells 11,509 Shares of Ultragenyx Pharmaceutical ... (GuruFocus.com)
Mar-11-24 03:00PM	Director Matthew Fust Sells 12,195 Shares of Ultragenyx Pharmaceutical Inc (RARE) (GuruFocus.com)
Mar-08-24 09:38AM	10 Biotech Stocks with Huge Potential (Insider Monkey)
Feb-27-24 04:30PM	Ultragenyx to Participate at Investor Conferences in March (GlobeNewswire) +6.79%
Feb-23-24 04:05PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-16-24 10:43AM	Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2023 Earnings Call Transcript (Insider Monkey) +5.75%
10:35AM	Q4 2023 Ultragenyx Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
07:53AM	Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat (Zacks)
Feb-15-24 04:15PM	Ultragenyx: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update (GlobeNewswire)
Feb-13-24 01:36PM	15 Best Strong Buy Stocks To Invest In (Insider Monkey) -5.91%
Feb-08-24 04:00PM	Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update (GlobeNewswire)
Feb-06-24 08:00AM	Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
04:05PM	Loading…
Feb-05-24 04:05PM	Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome (GlobeNewswire)
Jan-25-24 04:05PM	Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease (GlobeNewswire)
Jan-19-24 04:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-18-24 02:41PM	Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83 (Investor's Business Daily)
Jan-09-24 06:20PM	After Golden Cross, Ultragenyx (RARE)'s Technical Outlook is Bright (Zacks)
Jan-08-24 12:18PM	Ultragenyx's (RARE) Preliminary 2023 Revenues Disappoint (Zacks)
07:00AM	Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments (GlobeNewswire)
Jan-07-24 11:00AM	Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones (GlobeNewswire)
Jan-04-24 08:12AM	Ultragenyx (RARE) Posts Update From AS Study of GTX-102 (Zacks)
08:00AM	Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH) (GlobeNewswire)
Jan-03-24 08:00AM	Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome (GlobeNewswire)
Jan-02-24 04:05PM	Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-27-23 06:41PM	13 Most Promising Future Stocks To Buy According To Hedge Funds (Insider Monkey)
Dec-21-23 05:21PM	Ultragenyx to Pay $6 Million to Settle Alleged False Medicare, Medicaid Claims (The Wall Street Journal)
04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-18-23 09:29AM	Andelyn Biosciences Selected by Ultragenyx for Late-Stage Process Performance Qualification (PPQ) Manufacturing of Novel Gene Therapy for Sanfilippo Syndrome (PR Newswire)
08:00AM	Ultragenyx Receives European Commission Decision for Evkeeza (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH) (GlobeNewswire)
Dec-15-23 10:18AM	5 Most Promising Biotech Stocks to Buy According to Analysts (Insider Monkey)
Nov-20-23 04:30PM	Ultragenyx to Participate at Investor Conferences in November (GlobeNewswire)
Nov-17-23 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-07-23 05:00PM	Ultragenyx to Participate in the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-04-23 01:12PM	Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q3 2023 Earnings Call Transcript (Insider Monkey)
12:16PM	12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds (Insider Monkey)
Nov-03-23 11:43AM	Ultragenyx (RARE) Q3 Earnings and Revenues Miss Estimates (Zacks) +6.09%
Nov-02-23 06:26PM	Ultragenyx Pharmaceutical Inc (RARE) Reports Q3 2023 Earnings: Revenue Grows by 8% Year-Over-Year (GuruFocus.com)
04:36PM	Ultragenyx: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update (GlobeNewswire)
Oct-26-23 04:05PM	Ultragenyx to Host Conference Call for Third Quarter 2023 Financial Results and Corporate Update (GlobeNewswire) +5.12%
Oct-25-23 06:17AM	Insider Sell: CBO & EVP Thomas Kassberg Sells 39,878 Shares of Ultragenyx Pharmaceutical Inc (GuruFocus.com)
Oct-23-23 04:01PM	Ultragenyx Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
04:01PM	Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update (GlobeNewswire)
Oct-20-23 04:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-18-23 09:16PM	Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -13.85%
Oct-17-23 04:02PM	Ultragenyx Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Oct-16-23 08:00AM	Ultragenyx Announces Program and Pipeline Updates at Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (OI), Angelman Syndrome (AS) and Wilson Disease (GlobeNewswire) +10.28%
Oct-14-23 04:30PM	Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI) (GlobeNewswire)
Oct-12-23 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.98%
Oct-09-23 08:00AM	Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI) (GlobeNewswire)
Oct-05-23 08:00AM	Ultragenyx to Present Pipeline Update at Analyst Day on Monday, October 16, 2023 (GlobeNewswire)
Sep-25-23 05:13PM	Ultragenyx Launches Evkeeza® (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) (GlobeNewswire)
Sep-20-23 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-07-23 12:36PM	Is Ultragenyx Pharmaceutical (RARE) Too Good to Be True? A Comprehensive Analysis of a ... (GuruFocus.com) +6.06%
Aug-31-23 09:00AM	Ultragenyx to Participate at Investor Conferences in September (GlobeNewswire)
Aug-18-23 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-12-23 11:05AM	10 Oversold Healthcare Stocks to Buy (Insider Monkey)
Aug-11-23 11:14AM	Henrietta Lacks' estate sues Ultragenyx over Mass.-made gene therapies (American City Business Journals)
Aug-10-23 06:27PM	Henrietta Lacks' family sues Ultragenyx over use of HeLa cell line (Reuters)
Aug-08-23 07:11AM	Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 41% Below Their Intrinsic Value Estimate (Simply Wall St.)
06:20AM	15 Worst Performing Biotech Stocks in 2023 (Insider Monkey)
Aug-04-23 08:34AM	Q2 2023 Ultragenyx Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents) -8.79%
08:12AM	Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat (Zacks)
Aug-03-23 04:09PM	Ultragenyx: Q2 Earnings Snapshot (AP Finance)
04:00PM	Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update (GlobeNewswire)
Jul-31-23 08:00AM	Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease (GlobeNewswire)
Jul-27-23 05:00PM	Ultragenyx to Host Conference Call for Second Quarter 2023 Financial Results and Corporate Update (GlobeNewswire)
05:05AM	Can Mass. move beyond R&D to become a biomanufacturing leader? (American City Business Journals)
Jul-18-23 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-13-23 03:00PM	10 Best Revenue Growth Stocks to Buy (Insider Monkey)
Jul-12-23 08:00AM	Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy (GlobeNewswire)
Jul-07-23 07:46AM	Ultragenyx (RARE) Doses First Patients in Bone Disease Studies (Zacks)
Jul-06-23 08:00AM	Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) (GlobeNewswire)
Jun-28-23 11:06AM	This Biotech Stock Could Be a RARE Find (TheStreet.com)
Jun-21-23 08:00AM	Ultragenyx Opens New Gene Therapy Manufacturing Facility in Bedford, Continuing its Expansion in Massachusetts (GlobeNewswire)
Jun-20-23 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-09-23 10:55AM	13 Best Future Stocks for the Long-Term (Insider Monkey)
Jun-07-23 05:00PM	Ultragenyx to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
03:21AM	4 big analyst picks: YEXT riding high (Investing.com)
Jun-05-23 04:00PM	Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI) (GlobeNewswire)
May-24-23 06:39AM	Strong week for Ultragenyx Pharmaceutical (NASDAQ:RARE) shareholders doesn't alleviate pain of three-year loss (Simply Wall St.)
May-19-23 08:30AM	Ultragenyx to Present at the 2023 Barclays - Gene Editing & Gene Therapy Summit (GlobeNewswire)

Ultragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Crombez Eric	EVP and Chief Medical Officer	Apr 18 '24	Sale	44.10	142	6,262	48,785	Apr 19 04:35 PM
Kassberg Thomas Richard	CBO & EVP	Mar 11 '24	Sale	49.93	11,509	574,644	252,823	Mar 12 01:41 PM
Fust Matthew K	Director	Mar 07 '24	Sale	50.88	12,195	620,443	14,860	Mar 11 12:54 PM
Harris Erik	EVP & Chief Commercial Officer	Mar 01 '24	Sale	53.76	4,768	256,328	67,163	Mar 05 08:08 PM
Pinion John Richard	See Remarks	Mar 01 '24	Sale	53.76	4,173	224,340	89,268	Mar 05 08:15 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Mar 01 '24	Sale	53.76	3,756	201,923	67,340	Mar 05 08:22 PM
Crombez Eric	EVP and Chief Medical Officer	Mar 01 '24	Sale	53.76	1,238	66,555	48,927	Mar 05 08:10 PM
Kassberg Thomas Richard	CBO & EVP	Mar 01 '24	Sale	53.76	1,011	54,351	264,332	Mar 05 08:19 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Mar 01 '24	Sale	53.76	341	18,332	41,380	Mar 05 08:13 PM
KAKKIS EMIL D	President & CEO	Feb 07 '24	Sale	45.00	30,000	1,350,000	539,770	Feb 08 03:49 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Jan 02 '24	Option Exercise	21.00	3,000	63,000	27,892	Jan 02 04:06 PM
KAKKIS EMIL D	President & CEO	Dec 29 '23	Sale	47.87	30,000	1,436,100	569,770	Jan 02 04:07 PM
Kassberg Thomas Richard	CBO & EVP	Oct 23 '23	Option Exercise	6.86	39,878	273,563	286,738	Oct 24 05:22 PM
Kassberg Thomas Richard	CBO & EVP	Oct 23 '23	Sale	32.78	39,878	1,307,201	246,860	Oct 24 05:22 PM
KAKKIS EMIL D	President & CEO	Oct 19 '23	Option Exercise	6.86	47,853	328,272	647,029	Oct 23 05:14 PM
KAKKIS EMIL D	President & CEO	Oct 19 '23	Sale	33.52	47,853	1,604,033	599,743	Oct 23 05:14 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 07 '23	Option Exercise	21.00	2,000	42,000	25,777	Sep 11 01:52 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 07 '23	Sale	40.80	2,163	88,249	23,614	Sep 11 01:52 PM
Harris Erik	EVP & Chief Commercial Officer	Sep 05 '23	Sale	37.96	6,000	227,760	51,281	Sep 06 05:51 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 01 '23	Sale	37.15	970	36,032	23,777	Sep 06 05:50 PM
Sanders Corazon (Corsee) D.	Director	Jun 30 '23	Sale	46.76	585	27,355	8,985	Jun 30 02:34 PM
Harris Erik	EVP & Chief Commercial Officer	Jun 19 '23	Sale	48.20	305	14,701	57,281	Jun 21 06:17 PM
Sanders Corazon (Corsee) D.	Director	Jun 08 '23	Sale	51.65	1,485	76,700	9,570	Jun 09 02:31 PM
Pinion John Richard	See Remarks	May 18 '23	Sale	50.00	2,012	100,600	74,744	May 19 01:54 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	May 09 '23	Option Exercise	21.00	3,000	63,000	30,747	May 10 08:09 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	May 04 '23	Sale	45.00	4,378	197,010	51,982	May 05 02:16 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

ATRA

Atara Biotherapeutics Inc

CRNX

Crinetics Pharmaceuticals Inc

RARE

Ultragenyx Pharmaceutical Inc.

Upgrade your FINVIZ experience